Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are starting, or have recently started (within the last 2 weeks), a type of prostate cancer hormone therapy called an androgen receptor axis-targeted therapy (ARAT), or who are switching to a different ARAT because their previous one stopped working or caused side effects
- People who have been diagnosed with either metastatic prostate cancer (cancer that has spread, whether or not it responds to hormone-lowering treatment) or non-metastatic castration-resistant prostate cancer (cancer that has not spread but is no longer responding to hormone-lowering treatment)
- People who are at least 65 years old
- People who are able to give written consent to participate
- People who have access to a working telephone
Who may not be able to join:
- People who are not able to speak English, as the support calls from the nurse are conducted by phone and the study materials are not available in other languages
- People who have been diagnosed with a serious mental health or cognitive condition, such as severe depression or moderate-to-severe dementia
- People whose oncologist estimates their life expectancy to be less than 3 months
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Shabbir Alibhai, MD, UHN - Princess Margaret Cancer Centre
Phone: (416) 340-5125
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with Grade 3-5 Toxicity; Health related quality of life in patients with metastatic prostate cancer
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.